The origins and formation of bone-resorbing osteoclasts.


Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
11 2022
Historique:
received: 09 06 2022
revised: 17 08 2022
accepted: 18 08 2022
pubmed: 27 8 2022
medline: 28 9 2022
entrez: 26 8 2022
Statut: ppublish

Résumé

Osteoclasts (OCLs) are hematopoietic cells whose physiological function is to degrade bone. OCLs are key players in the processes that determine and maintain the mass, shape, and physical properties of bone. OCLs adhere to bone tightly and degrade its matrix by secreting protons and proteases onto the underlying surface. The combination of low pH and proteases degrades the mineral and protein components of the matrix and forms a resorption pit; the degraded material is internalized by the cell and then secreted into the circulation. Insufficient or excessive activity of OCLs can lead to significant changes in bone and either cause or exacerbate symptoms of diseases, as in osteoporosis, osteopetrosis, and cancer-induced bone lysis. OCLs are derived from monocyte-macrophage precursor cells whose origins are in two distinct embryonic cell lineages - erythromyeloid progenitor cells of the yolk sac, and hematopoietic stem cells. OCLs are formed in a multi-stage process that is induced by the cytokines M-CSF and RANKL, during which the cells differentiate, fuse to form multi-nucleated cells, and then differentiate further to become mature, bone-resorbing OCLs. Recent studies indicate that OCLs can undergo fission in vivo to generate smaller cells, called "osteomorphs", that can be "re-cycled" by fusing with other cells to form new OCLs. In this review we describe OCLs and discuss their cellular origins and the cellular and molecular events that drive osteoclastogenesis.

Identifiants

pubmed: 36028118
pii: S8756-3282(22)00215-0
doi: 10.1016/j.bone.2022.116538
pii:
doi:

Substances chimiques

Protons 0
Macrophage Colony-Stimulating Factor 81627-83-0
Peptide Hydrolases EC 3.4.-

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

116538

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Ari Elson (A)

Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel. Electronic address: ari.elson@weizmann.ac.il.

Anuj Anuj (A)

Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel.

Maayan Barnea-Zohar (M)

Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel.

Nina Reuven (N)

Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH